<!DOCTYPE html>
<html lang="en">
	<head>
		<!-- Required meta tags -->
		<meta charset="utf-8" />
		<meta name="viewport" content="width=device-width, initial-scale=1" />
		<style>
			@import url("https://fonts.googleapis.com/css2?family=Montserrat:ital,wght@0,100;0,300;0,400;1,100;1,300;1,400&family=Open+Sans:wght@300;400&display=swap");
		</style>

		<!-- Bootstrap CSS -->
		<link
			href="https://cdn.jsdelivr.net/npm/bootstrap@5.0.1/dist/css/bootstrap.min.css"
			rel="stylesheet"
			integrity="sha384-+0n0xVW2eSR5OomGNYDnhzAbDsOXxcvSN1TPprVMTNDbiYZCxYbOOl7+AMvyTG2x"
			crossorigin="anonymous"
		/>
		<link href="style.css" rel="stylesheet" />
		<title>Technology</title>
	</head>
	<body>
		<!-- navbar -->
		<nav class="navbar navbar-dark navbar-expand-lg sticky-top">
			<div class="container">
				<a class="navbar-brand" style="padding-top: 0; padding-bottom: 0">
					<img src="Kurve.png" alt="Kurve Logo" width="146" height="90" />
				</a>
				<button
					class="navbar-toggler custom-toggler"
					type="button"
					data-bs-toggle="collapse"
					data-bs-target="#navbarNavDropdown"
					aria-controls="navbarNavDropdown"
					aria-expanded="false"
					aria-label="Toggle navigation"
				>
					<span class="navbar-toggler-icon"></span>
				</button>
				<div class="collapse navbar-collapse" id="navbarNavDropdown">
					<ul class="navbar-nav">
						<li class="nav-item">
							<a class="nav-link active" aria-current="page" href="index.html"
								>Home</a
							>
						</li>
						<li class="nav-item">
							<a class="nav-link" href="technology.html">Technology</a>
						</li>
						<li class="nav-item">
							<a class="nav-link" href="targetD.html">Target Diseases</a>
						</li>
						<li class="nav-item dropdown">
							<a
								class="nav-link dropdown-toggle"
								href="#"
								id="navbarDropdownMenuLink"
								role="button"
								data-bs-toggle="dropdown"
								aria-expanded="false"
							>
								Results
							</a>
							<ul
								class="dropdown-menu"
								aria-labelledby="navbarDropdownMenuLink"
							>
								<li>
									<a class="dropdown-item" href="phase_I.html"
										>Early Clincal Results: Suggestion of Relevance in
										Alzheimer’s Disease</a
									>
								</li>
								<li>
									<a class="dropdown-item" href="phase_II.html"
										>Phase II Clincal Results: Proof of Concept as
										Disease-Modifying in Alzheimer’s</a
									>
								</li>
							</ul>
						</li>
						<li class="nav-item dropdown">
							<a
								class="nav-link dropdown-toggle"
								href="#"
								id="navbarDropdownMenuLink"
								role="button"
								data-bs-toggle="dropdown"
								aria-expanded="false"
							>
								About
							</a>
							<ul
								class="dropdown-menu"
								aria-labelledby="navbarDropdownMenuLink"
							>
								<li>
									<a class="dropdown-item" href="about.html"
										>Kurve Therapeutics</a
									>
								</li>
								<li><a class="dropdown-item" href="team.html">Team</a></li>
							</ul>
						</li>
					</ul>
				</div>
			</div>
		</nav>
		<!-- /navbar -->
		<!-- body content -->
		<div class="tech">
		<div class="container">
			<div class="card technology container" style="width:100%; margin: auto; border-color: #fff;">
				<!-- <img src="..." class="card-img-top" alt="..."> -->
				<div class="card-body">
				  <p class="phase card-text"><span class="lead" style="color: #0f568a;">Kurve’s patented Controlled Particle Dispersion® (CPD) technology</span> enhances significantly the efficacy and safety of existing and new formulations. This is done by accessing the most-penetrable part of the blood-brain barrier (BBB), the olfactory mucosa at the top of the nasal cavity, where nerves penetrate to convey smell signals to the brain. 
					  This approach, known as the nose-to-brain route, is particularly important for large, complex molecules (e.g., proteins, antibodies) that have shown promise in neurodegenerative disease but are virtually impossible to deliver to the brain via other non-surgical routes (oral, intravenous, etc.)</p>
				  <p class="phase card-text">Kurve CPD’s precisely-controlled turbulent flow generation, unlike other technologies, gets medicines past the curved surfaces inside the nose and up to the olfactory mucosa. This capability was demonstrated in an 18-month Phase II Alzheimer’s disease study using two different nasal delivery technologies. 
					  Patients using the Kurve device showed improvement vs. baseline and placebo; the patients using the other device deteriorated from baseline (publication pending).<br>
					  In a smaller, four-month Phase II study using PET scanning, Alzheimer’s patients using a Kurve drug/device product demonstrated enhanced activity vs. placebo in compromised brain regions.
					</p>
				  <p class="phase card-text">Kurve’s intellectual property for delivery devices is covered by 15 issued patents and 6 pending patents. Kurve had its first patent issued (and a second approved) by the USPTO in 2007.  
					  The earlier patents are in effect until 2027 with further patents in place until 2032; further patents are pending. Patents have been awarded in the USA, EU, and Japan.</p>
				</div>
				<div class="px-3"><hr class="my-4"></div>
				<div class="card-body">
				<h5 class="card-title">Kurve drug/device platform features and benefits:</h5>
				</div>
				<ul class="list-unstyled">
                    <li>
                      <ul>
                        <li>Distribution to targeted location: Increases efficacy through better access to target organs / tissues. Conversely, reduces side-effects (less drug going to non-targeted areas)</li>
                        <li>Enhanced bioavailability (drug distribution to target organs and tissues): CPD delivers droplets that rest below the zone of ciliated action, allowing for longer residence time, thus improving absorption and accelerating onset of action</li>
                        <li>Enhanced dosage precision: Programmable electronic circuitry plus advanced mechanics deliver precise amounts of drug while significantly enhancing concentration in the desired nasal cavity area (and thus delivery to target organs/tissues)</li>
                        <li>Enhanced Patient Compliance: Non-invasive, simplified, user-friendly modes of administration encourage patient acceptance/use and minimize application errors. Delivery tend to be odorless, tasteless and painless</li>
                      </ul>
                    </li>
                  </ul>
				<div class="card-body">
					<h5 class="card-title">Kurve drug/device platform features and benefits:</h5>
					<p class="phase card-text">Odorless, tasteless and painless drug delivery is made possible with the Kurve technology platform. Dosage is usually twice daily for about 15 seconds each time. All of this is done with a pocket-sized, light, portable, battery-powered device.</p>
				</div>
			  </div>

		</div>
	</div>

		<!--/body content-->

		<!-- Optional JavaScript; choose one of the two! -->

		<!-- Option 1: Bootstrap Bundle with Popper -->
		<script
			src="https://cdn.jsdelivr.net/npm/bootstrap@5.0.1/dist/js/bootstrap.bundle.min.js"
			integrity="sha384-gtEjrD/SeCtmISkJkNUaaKMoLD0//ElJ19smozuHV6z3Iehds+3Ulb9Bn9Plx0x4"
			crossorigin="anonymous"
		></script>

		<!-- Option 2: Separate Popper and Bootstrap JS -->
		<!--
    <script src="https://cdn.jsdelivr.net/npm/@popperjs/core@2.9.2/dist/umd/popper.min.js" integrity="sha384-IQsoLXl5PILFhosVNubq5LC7Qb9DXgDA9i+tQ8Zj3iwWAwPtgFTxbJ8NT4GN1R8p" crossorigin="anonymous"></script>
    <script src="https://cdn.jsdelivr.net/npm/bootstrap@5.0.1/dist/js/bootstrap.min.js" integrity="sha384-Atwg2Pkwv9vp0ygtn1JAojH0nYbwNJLPhwyoVbhoPwBhjQPR5VtM2+xf0Uwh9KtT" crossorigin="anonymous"></script>
    -->
	</body>
</html>
